| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5540 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2869 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1744 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1389 | 2021 |
| What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 SH Hodgson, K Mansatta, G Mallett, V Harris, KRW Emary, AJ Pollard The lancet infectious diseases 21 (2), e26-e35, 2021 | 791 | 2021 |
| The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells Z Hu, M Artibani, A Alsaadi, N Wietek, M Morotti, T Shi, Z Zhong, ... Cancer cell 37 (2), 226-242. e7, 2020 | 146 | 2020 |
| Impaired antibody response to COVID‐19 vaccination in patients with chronic myeloid neoplasms O Chowdhury, H Bruguier, G Mallett, N Sousos, K Crozier, C Allman, ... British journal of haematology 194 (6), 1010, 2021 | 36 | 2021 |
| Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells M Artibani, K Masuda, Z Hu, PC Rauher, G Mallett, N Wietek, M Morotti, ... JCI insight 6 (11), 2021 | 12 | 2021 |
| Cross-sectional Survey of Medical student Attitudes to Research and Training pathways (SMART) in the UK: study protocol S Roche, S Bandyopadhyay, A Grassam-Rowe, RA Brown, P Iveson, ... BMJ open 11 (9), e050104, 2021 | 6 | 2021 |
| The Oxford Ovarian Cancer Predict Chemotherapy Response (OXO-PCR) study: Understanding the genomic drivers of primary chemotherapy-resistant microscopic residual disease M Artibani, G Mallett, D Sunanda, M KaramiNejadRanjbar, M Morotti, ... Cancer Research 78 (13_Supplement), 5373-5373, 2018 | | 2018 |
| The repertoire of serous ovarian cancer non-genetic heterogeneity revealed by single-cell sequencing of normal fallopian tube epithelial cells LS Gonzalez, S El-Sahhar, M KaramiNejadRanjbar, G Mallett | | |
